CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 500 filers reported holding CRISPR THERAPEUTICS AG in Q2 2021. The put-call ratio across all filers is 1.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $225,009 | +6.3% | 4,008 | -14.3% | 0.13% | 0.0% |
| Q1 2023 | $211,631 | -1.8% | 4,679 | -11.7% | 0.13% | -10.9% |
| Q4 2022 | $215,486 | -93.9% | 5,301 | -90.2% | 0.15% | -93.9% |
| Q3 2022 | $3,525,000 | +679.9% | 53,944 | +625.8% | 2.43% | +653.7% |
| Q2 2022 | $452,000 | -1.1% | 7,432 | +2.1% | 0.32% | +11.0% |
| Q1 2022 | $457,000 | -28.9% | 7,278 | -14.3% | 0.29% | -26.6% |
| Q4 2021 | $643,000 | -0.2% | 8,489 | +47.6% | 0.40% | -6.6% |
| Q3 2021 | $644,000 | -30.3% | 5,750 | +0.8% | 0.42% | -25.5% |
| Q2 2021 | $924,000 | +63.8% | 5,707 | +23.3% | 0.57% | +55.6% |
| Q1 2021 | $564,000 | -12.7% | 4,630 | +9.8% | 0.36% | -17.4% |
| Q4 2020 | $646,000 | +101.9% | 4,218 | +10.1% | 0.44% | +71.3% |
| Q3 2020 | $320,000 | +19.0% | 3,830 | +4.7% | 0.26% | +15.7% |
| Q2 2020 | $269,000 | – | 3,657 | – | 0.22% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |